Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind ritlecitinib trial in moderate alopecia areata
jRCT2031260419Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in alopecia areata (7 arms), sponsored by Pfizer. Primary endpoint: Proportion of SALT 0 responders at Week 24. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on jRCT2031260419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260419.